What is Chemotherapy?
Chemotherapy is a group of toxic drugs that kill cells (mesothelioma, other cancers, and healthy cells) by damaging their DNA. Chemotherapy is a cytotoxic therapy, meaning it kills cells. Chemo drugs target rapidly growing cancer cells, but they can also affect healthy cells that grow rapidly such as blood cells. The effect of these drugs on both cancer and normal cells often causes chemo side effects.
Alimta (Pemetrexed) and Cisplatin
As of this writing, the only FDA approved chemotherapy for mesothelioma is a combination of Alimta (pemetrexed) and cisplatin. In February 2004, the Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma in combination with cisplatin for patients whose disease is either inoperable or who are not otherwise candidates for curative surgery. Patients who take this chemo regimen are often prescribed folic acid and vitamin B12 supplement to help reduce side effects from the chemotherpay. Patients are usually prescribed corticosteroids to reduce the risk of skin rashes as well.
The recommended dose of pemetrexed is 500 mg/m administered as an intravenous infusion over 10 minutes on day 1 of each 21-day cycle together with cisplatin at a dose of 75 mg/m infused over 2 hours beginning 30 minutes after the pemetrexed infusion.
The Clinical Trial that Approved Alimta (Pemetrexed) and Cisplatin
There was one key clinical trial that led to the FDA approval of this regimen for mesothelioma. Two hundred twenty-six pleural mesothelioma patients were randomized to receive pemetrexed and cisplatin, while 222 patients were randomized to receive cisplatin alone. The primary study end point was survival. Median survival times were 12.1 months for the pemetrexed plus cisplatin treatment group and 9.3 months for the cisplatin alone group.
Median time to progression (regrowth of tumor) was longer in the pemetrexed/cisplatin arm of the study, 5.7 months versus 3.9 months. This means that the mesothelioma patients who received both drugs had their tumors return a median of 1.8 months longer versus those who only got one drug.
Like most chemo drugs, pemetrexed kills blood cells so the most common adverse events were neutropenia, fatigue, leukopenia, nausea, dyspnea, and vomiting.
On February 4, 2004, pemetrexed was approved by the FDA in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is inoperable or who are otherwise not candidates for curative surgery.
Related Posts
Unlocking the Power of Vitamin A: Tretinoin Enhances Cancer Treatment - Tretinoin is a derivative of vitamin A. It shows the potential to enhance the effects of chemotherapy. Combining tretinoin with chemotherapy improved survival rates in mesothelioma in mice. Chemotherapy Response in Mesothelioma Mesothelioma is a rare type of cancer that is hard to diagnose and treat. It develops from the thin layer of tissue that covers many of the body’s internal organs. Mesothelioma is caused by exposure to a toxic mineral called asbestos. In most cases, doctors will use more than one type of treatment to remove as many cancer cells as possible from a patient’s body. The standard therapies include chemotherapy, radiation, and surgery. When a patient gets chemotherapy treatment, they are given drugs that kill cells by damaging their DNA. Currently, the only...
Mesothelioma Treatment: What You Need to Know about Nivolumab and Ipilimumab - Mesothelioma is a rare and tough kind of cancer, often linked to exposure to something called asbestos. Scientists are exploring new ways to treat it, and one promising method is using a combination of two drugs: nivolumab and ipilimumab. A new study looks at what these drugs do and shares some real-world information. The results show how researchers are helping people with mesothelioma. Mesothelioma is a kind of cancer that shows up in the lining around organs like the lungs, abdomen, and heart. It’s connected to exposure to asbestos, which is a harmful substance that used to be widely used in construction and other industries. The Nivolumab and Ipilimumab Combo Scientists have been testing a combo of two drugs –...
Understanding Mesothelioma: Clues from Calretinin for Patients - Malignant mesothelioma is a tough cancer caused by asbestos. It’s hard to treat because it grows quickly and is tough to beat. A recent study took a close look at a protein called calretinin. Scientists wanted to see if it could help predict how long someone might live with this cancer and how well they might respond to treatment. A Possible Game-Changer in Mesothelioma Care The study looked at 265 patients with this mesothelioma. They checked how much calretinin was in their blood and looked at the genes linked to how calretinin works. Scientists used tests to measure calretinin and found differences in genes among patients. Then they checked if these things were connected to how long patients lived or...
New Hope for Pleural Mesothelioma: Targeting YB-1 for Enhanced Treatment - Pleural mesothelioma has been challenging to treat with limited options and a poor outlook. But, researchers have uncovered a promising new way to improve chemotherapy and radiotherapy. This exciting breakthrough means new treatment options for mesothelioma treatment. Understanding YB-1 in Mesothelioma A new study focused on a protein called Y-box-binding protein 1 (YB-1). Previous research has shown that YB-1 plays a role in controlling various aspects of pleural mesothelioma. It plays a role in cancer cell growth, cell death, and cell movement. Building on this knowledge, the researchers set out to see if targeting YB-1 could make treatments more effective. To target YB-1, the researchers used small interfering RNA to “knock down” YB-1. This significantly reduced tumor growth. This also...
Promising Results: Pembrolizumab Enhances Mesothelioma Treatment - Pleural mesothelioma is a challenging cancer caused by asbestos exposure. It is often diagnosed in advanced stages with limited treatment options. However, a glimmer of hope has emerged in recent years with a groundbreaking approach. The addition of pembrolizumab to standard chemotherapy has shown promising results in improving the overall survival of patients with this devastating disease. A Global Effort A phase 3 clinical trial was conducted across 51 hospitals in Canada, Italy, and France. Eligible participants, aged 18 years or older, had previously untreated advanced pleural mesothelioma and a good performance status. They were randomly divided into two groups. One received intravenous chemotherapy with or without pembrolizumab. A Game-Changing Outcome The trial ran from January 2017 to September 2020...
Safety First: Managing Cisplatin Exposure After Mesothelioma Treatment - Mesothelioma is an aggressive type of cancer that affects the lining of the lungs, abdomen, or heart. It is caused by exposure to a mineral called asbestos. Mesothelioma can be difficult to treat, and doctors use a combination of treatments to help patients. One of these treatments is called Hyperthermic Intrathoracic Chemotherapy (HITOC), which delivers a drug called cisplatin directly to the area where the cancer is found. Decoding Mesothelioma Treatment A recent study aimed to learn more about the safety measures needed after HITOC. The researchers focused on understanding how cisplatin is removed from the body through fluids like blood, urine, and secretions from the lungs. They collected samples from five patients who underwent HITOC, both before and after... A Step Forward in Treating Pleural Mesothelioma: The Pembrolizumab and Lenvatinib Combination - Pleural mesothelioma is a rare and aggressive cancer that has been challenging to treat effectively. However, recent breakthroughs in medical research are shedding new light on potential treatment options. Researchers investigated the potential of a combination therapy involving pembrolizumab and lenvatinib. Their findings were promising, with over 50% of patients experiencing tumor shrinkage. While this marks an important step forward, challenges such as side effects need to be carefully addressed in future research. Uncovering Hope for Pleural Mesothelioma Pleural mesothelioma is a rare and aggressive form of cancer that affects the lining of the lungs. It’s linked to exposure to a harmful substance called asbestos. Asbestos used to be used a lot in construction and other industries. Finding good treatments...
Choosing the Right Mesothelioma Treatment: A Cost-Effective Perspective - A recent study unveiled intriguing findings about the cost-effectiveness of mesothelioma treatments. Standard chemotherapy is the tried-and-true pemetrexed plus cisplatin combination. But how does it measure up against a newer but pricier alternative, nivolumab plus ipilimumab? The Gold Standard Treatment Malignant pleural mesothelioma is an aggressive type of cancer that affects the lining of the lungs. It is caused by exposure to a toxic mineral called asbestos. Conventional treatments for mesothelioma generally consist of chemotherapy, surgery, and sometimes radiation therapy. The standard chemotherapy treatment for mesothelioma is a combination of two drugs called pemetrexed and cisplatin. This is the only FDA-approved chemotherapy regimen for mesothelioma. Recently, a new combination of drugs has been found to be even better at shrinking...
The Crucial Role of Initial Tests in Mesothelioma Treatment - Mesothelioma diagnosis and treatment begin with a series of initial tests to determine the specific type of the disease. A recent study explored these tests and their accuracy in predicting mesothelioma types. Discover why getting it right from the start can be a matter of life and death for mesothelioma patients. Prognosis and Treatment Mesothelioma is a type of cancer that affects the lining of the lungs and other organs. Doctors often use surgery to remove the cancer. In some cases, they also use chemotherapy before the surgery to shrink the tumor. Before starting treatment, doctors conduct tests to figure out what type of mesothelioma their patient has. A recent study looked at how accurate the initial tests were in...
A Game-Changer in Mesothelioma Therapy: Targeting YB-1 Protein - An international team of researchers has discovered a unique YB-1 protein. It can make chemotherapy more effective at treating mesothelioma. Combating Mesothelioma with Precision Mesothelioma is an aggressive type of cancer, especially when it affects the lining around our lungs. It is caused by exposure to asbestos. Finding effective treatments has been a challenge, but recent research has brought a ray of hope. Scientists have been studying a particular protein called Y-box-binding protein 1 (YB-1). It plays a vital role in the growth and movement of mesothelioma cells. When treating mesothelioma, one of the main approaches is chemotherapy. This powerful treatment uses drugs to target and kill cancer cells. The only FDA-approved chemotherapy drug combination is pemetrexed with cisplatin. Sometimes,...